Rx-360 Completes Pilot Audit of Manufacturing Facility: An Industry Case Study from Avantor - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Rx-360 Completes Pilot Audit of Manufacturing Facility: An Industry Case Study from Avantor
Avantor reviews its experience with the Rx-360 shared audit pilot program, which is aimed at protecting the pharmaceutical supply chain. This article is part of a special issue on Outsourcing.


Pharmaceutical Technology
Volume 35, pp. s59-s60

This article is part of a special issue on Outsourcing Resources

As pharmaceutical supply chains and distribution channels become more complex and global, there are renewed calls from public-health experts and Congress to ensure patient safety by demonstrating that supply chains are secure. A series of recent supply-chain breaches have demonstrated that a compromised supply chain is susceptible to counterfeit, diversion, dilution, tampering, and deliberate contamination—ultimately affecting thousands of patients every day.

In 2009, five bio/pharmaceutical manufacturers, distributors, and suppliers collaborated to form Rx–360, an international supply-chain consortium aimed at enhancing patient safety across the pharmaceutical supply chain. The voluntary group's mission is "to create and monitor a global quality system that meets the expectations of industry and regulators, and that assures patient safety by enhancing product quality and authenticity throughout the supply chain" (1). Today, Rx–360 has 64 members and continues to grow.

As part of fulfilling its mission, Rx-360 has begun conducting joint audits of its supplier members with the intention of sharing them with industry. These audits, designed to help establish and share best practices for supply-chain security, are designed to be more thorough than those conducted by individual pharmaceutical manufacturers because they focus on the entire supply chain from the origin of raw materials to shipment of product. Standards for the Rx–360 pilot audit, adopted by the Audit Standard Working Group, are based on the draft Excipact Excipient standard, the International Pharmaceutical Excipients Council/Pharmaceutical Quality Group (IPEC/PQG) Good Manufacturing Practices Audit Guide for Pharmaceutical Excipients, and the Rx–360 Basic Chemicals & Raw Materials Audit Guide (2, 3).

The audits carried out by Rx–360 are shared with the consortium's pharmaceutical manufacturer members, which regularly conduct their own independent audits of suppliers. The sharing of audit reports among industry is meant to reduce the number of repetitive audits hosted at a particular facility, allowing both pharmaceutical companies and suppliers to redirect resources toward higher risk suppliers and supply chains.

Rx-360 recently completed its first audit of a supplier member, Avantor Performance Materials, as part of a pilot program. This article describes Avantor's experience with the audit.

Background

Avantor Performance Materials, formerly Mallinckrodt Baker, joined Rx–360 in 2009. Avantor is a global supplier of critical performance chemistries and materials, including bulk pharmaceutical excipients, GMP-manufactured aqueous solutions, and process chromatography media.

Based in Phillipsburg, NJ, and with sites around the world, Avantor has a strong focus on supply-chain security. For example, the company operates a Certified Excipient Distributor program that is designed to assure customers that a certified Avantor channel partner uses fully documented chain of custody and change-management procedures. In collaboration with its suppliers, Avantor is also working to regularly review supply-management procedures; provide enhanced tamper-evident features on products; improve transportation-security measures; and to use advanced track-and-trace technology.

Several companies volunteered to participate in Rx–360's pilot audit program. The consortium conducted an internal survey of its manufacturers to determine which companies were suitable for participation. The goal was to choose suppliers whose audit results would be applicable and relevant to as many manufacturers as possible (4). As a broad supplier to many of the consortium's members, Avantor was selected, among other companies, to participate in the pilot. Avantor was the first supplier to have availability to host an audit, which was conducted in April 2011.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here